External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology AASLD Liver meeting 2024
Roche and Genentech at

AASLD Liver meeting 2024

November 15 - November 19
San Diago, CA
annualsummit2024
We will be contributing to topics related to
Oncology Infectious Disease
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
03:00 PM
Duration 9hrs San Diago, CA
Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapy in chronic hepatitis B: 48 week follow-up results from Piranga, a phase 2, randomized, controlled, adaptive, open-label platform study
Jinlin Hou, Qing Xie, Wenhong Zhang, Luis Enrique Morano Amado, Sheng-Shun Yang, Jidong Jia, Cheng-Yuan Peng, Wei-Wen Su, Jia-Horng Kao, Man-Fung Yuen, Tarik Asselah, Tawesak Tanwandee, Xieer Liang, Maria Teresa Catanese, Ethan Chen, Cong Cheng, Farouk Chughlay, Sudip Das, Katerina Glavini, Nelson Guerreiro, Yan Huang, Priyanka Kakrana, Rémi Kazma, Avinash Patil, Ruchi Upmanyu, Cynthia Wat, Edward Gane
Infectious Disease | Hepatitis B

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 9hrs San Diago, CA
Pharmacokinetic/pharmacodynamic modelling of RG6084 effects on hepatitis B surface antigen and alanine transaminase to inform Phase 2 dosing regimen selection
Sijie Lu, Sylvie Retout, Vedran Pavlovic, Greg Hooper, Gemma Attley, Annabelle Lemenuel-Diot
Infectious Disease | Hepatitis B

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 9hrs San Diago, CA
Factors associated with type of first-line treatment received for unresectable hepatocellular carcinoma in the era of immunotherapy
Cheng S, To TM, Schuldt R, Tan A
Oncology | Gastric Cancer - Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 9hrs San Diago, CA
Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
Karen Doucette, Deian Jelev, Jia-Horng Kao, Luis Enrique Morano Amado, Kosh Agarwal, Tarik Asselah, Anchalee Avihingsanon, Rozalina Balabanska, Wan-Long Chuang, Apinya Leerapun, Tien Huey Lim, Young-Suk Lim, Wei-Wen Su, Sheng-Shun Yang, Ed Gane, Gemma Attley, Maria Teresa Catanese, Farouk Chughlay, Anna Maria Geretti, Gregory Hooper, Rémi Kazma, Yukun Liang, Sijie Lu, Ruchi Upmanyu, Jeffrey Xu, Wen Zhang, Man-Fung Yuen
Infectious Disease | Hepatitis B

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 9hrs San Diago, CA
A novel mechanistic viral dynamics modeling (MVDM) framework to characterize and predict the effect of combination therapies in chronic hepatitis B: modeling of the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
Annabelle Lemenuel-Diot, Selma El Messaoudi, Jeremie Guedj, Sylvie Retout, Franziska Schaedeli-Stark, Amine Ait-Ali, Nelson Guerreiro, Sijie Lu, Farouk Chughlay, Claire McGeown, Rémi Kazma
Infectious Disease | Hepatitis B

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.